WhoHoldsbeta
StocksFundsHow it works
WhoHolds

Reverse holdings lookup for Indian markets. Paste a stock, see every mutual fund and ETF that holds it — with weight, value, and trend.

ExploreAll stocksAll fundsCompare brokersHow it works
Coverage451 funds1003 stocks10 fund houses
LegalDisclaimerPrivacyTermsRefund policyContact

Data sourced from public AMC monthly portfolio disclosures and the AMFI scheme master. Portfolios as on: Aditya Birla SL MF (Apr 2026) · Axis MF (—) · DSP MF (Apr 2026) · HDFC MF (Apr 2026) · ICICI Pru MF (Apr 2026) · Kotak MF (—) · Mirae Asset MF (—) · Nippon India MF (Jul 2025) · SBI MF (Apr 2026) · UTI MF (—). Holdings are ISIN-verified equity positions. For information only — not investment advice.

© 2026 WhoHolds · Built India-first at $0 fixed cost.

Search
AB
Sectoral / ThematicAditya Birla Sun Life Mutual Fund

Aditya Birla Sun Life Pharma & Healthcare Fund

Portfolio as on Apr 2026 · 38 equity positions

Equity positions
38
Equity value
₹888 Cr
Top holding
13.17%
Sun Pharmaceutical Industries Limited

Top holdings

#
1Sun Pharmaceutical Industries LimitedPharmaceuticals & Biotechnology
13.17%
₹118.64 Cr6.56 L
2Apollo Hospitals Enterprise LimitedHealthcare Services
7.20%
₹64.86 Cr84.9K
3Torrent Pharmaceuticals LimitedPharmaceuticals & Biotechnology
4.76%
₹42.87 Cr1.02 L
4JB Chemicals & Pharmaceuticals LimitedPharmaceuticals & Biotechnology
4.71%
₹42.40 Cr2.07 L
5Aurobindo Pharma LtdPharmaceuticals & Biotechnology
4.49%
₹40.47 Cr2.91 L
6Ajanta Pharma LtdPharmaceuticals & Biotechnology
4.05%
₹36.50 Cr1.29 L
7Lupin LtdPharmaceuticals & Biotechnology
4.00%
₹36.01 Cr1.56 L
8Mankind Pharma LtdPharmaceuticals & Biotechnology
3.88%
₹34.95 Cr1.56 L
9Fortis Healthcare LimitedHealthcare Services
3.87%
₹34.85 Cr3.78 L
10Abbott India LimitedPharmaceuticals & Biotechnology
3.65%
₹32.90 Cr12.9K
11Emcure Pharmaceuticals LtdPharmaceuticals & Biotechnology
3.32%
₹29.87 Cr1.78 L
12Cipla LimitedPharmaceuticals & Biotechnology
3.30%
₹29.74 Cr2.27 L
13IPCA Laboratories LimitedPharmaceuticals & Biotechnology
2.86%
₹25.80 Cr1.69 L
14Shilpa Medicare LtdPharmaceuticals & Biotechnology
2.51%
₹22.65 Cr5.57 L
15Corona Remedies LimitedPharmaceuticals & Biotechnology
2.24%
₹20.20 Cr1.17 L
16Sai Life Sciences LimitedPharmaceuticals & Biotechnology
2.20%
₹19.78 Cr1.85 L
17Alkem Laboratories LtdPharmaceuticals & Biotechnology
2.10%
₹18.92 Cr35.0K
18Procter & Gamble Health LimitedPharmaceuticals & Biotechnology
2.04%
₹18.36 Cr35.2K
19Divi's Laboratories LimitedPharmaceuticals & Biotechnology
1.88%
₹16.91 Cr26.0K
20Jupiter Life Line Hospitals LtdHealthcare Services
1.79%
₹16.11 Cr1.31 L
21SANOFI CONSUMER HEALTHCAREPharmaceuticals & Biotechnology
1.67%
₹15.03 Cr31.6K
22Thyrocare Technologies LimitedHealthcare Services
1.58%
₹14.19 Cr3.55 L
23Dr. Reddy's Laboratories LtdPharmaceuticals & Biotechnology
1.45%
₹13.09 Cr99.0K
24EQ - METROPOLIS HEALTHCARE LTDHealthcare Services
1.42%
₹12.80 Cr2.69 L
25Alembic Pharmaceuticals LimitedPharmaceuticals & Biotechnology
1.35%
₹12.16 Cr1.61 L
26Pfizer LimitedPharmaceuticals & Biotechnology
1.34%
₹12.04 Cr25.6K
27Jubilant Pharmova LimitedPharmaceuticals & Biotechnology
1.20%
₹10.83 Cr1.17 L
28Anthem Biosciences LtdPharmaceuticals & Biotechnology
1.20%
₹10.77 Cr1.42 L
29Biocon LtdPharmaceuticals & Biotechnology
1.08%
₹9.77 Cr2.72 L
30Suraksha Diagnostic LtdHealthcare Services
1.06%
₹9.50 Cr3.35 L
31Piramal Pharma LtdPharmaceuticals & Biotechnology
1.04%
₹9.36 Cr5.78 L
32Medi Assist Healthcare Services LtdInsurance
1.00%
₹9.02 Cr2.62 L
33Vijaya Diagnostic Centre LimitedHealthcare Services
0.98%
₹8.83 Cr78.2K
34Gland Pharma LimitedPharmaceuticals & Biotechnology
0.97%
₹8.75 Cr50.0K
35Dr. Lal Path Labs LimitedHealthcare Services
0.94%
₹8.51 Cr62.3K
36GlaxoSmithKline Pharmaceuticals LimitedPharmaceuticals & Biotechnology
0.85%
₹7.66 Cr32.8K
37Max Healthcare Institute LimitedHealthcare Services
0.77%
₹6.95 Cr70.0K
38Vinati Organics LimitedChemicals & Petrochemicals
0.69%
₹6.24 Cr47.2K

Equity holdings only, ISIN-verified, from Aditya Birla Sun Life Mutual Fund's public monthly portfolio disclosure (Apr 2026). Not investment advice.